Hyo Joon Kim | CTO
3H Bio Co., Ltd.
Dr. Hyo Joon Kim is the Chief Operating Officer of 3H Bio Co., Ltd. and Emeritus Professor at Hanyang University in Korea. Dr. Kim earned his Ph.D. from Osaka University and furthered his expertise through postdoctoral training at MIT’s Center for Cancer Research. His pioneering research focuses on utilizing a peptide mimotope (pB1) to induce "Conformational Cross-reactive Antibodies" against the autoantigen Apolipoprotein B-100. This method is designed to effectively block peripheral lipid absorption while avoiding side effects in the central nervous system. His breakthrough research was featured in World Biomedical Frontiers for its significant innovative impact. Recognized as one of the "100 Innovative Leaders in 2019” Dr. Kim is currently spearheading the development of the 3HOTP vaccine platform at 3H Bio. Under his leadership, the company projects the commencement of global clinical trials starting in 2026.
Appearances:
Pre-Congress Workshops - Monday 30th March @ 11:30
UNCONVENTIONAL VACCINES: OBESITY, ATHEROSCLEROSIS, AND ALZHEIMER’S DISEASE
This workshop explores the cutting edge of vaccinology, moving beyond infectious diseases to tackle the world’s most pressing chronic and metabolic conditions. Hosted by 3H Bio, the session brings together global pioneers to discuss how targeted immunological interventions can arrest the progression of atherosclerosis, Alzheimer’s, and obesity.
Attendees will gain insights into:
- Clinical breakthroughs in Tau-targeting vaccines for neurodegeneration.
- Novel platforms like mimotope vaccines for metabolic regulation.
- Translational challenges of moving unconventional vaccines from immunological theory to human clinical trials.
Join us to discover how the next generation of vaccines is being engineered to treat non-communicable diseases and reshape the future of preventative medicine.
11.30am Chair’s opening remarks:
Dr Kevin Killeen, President & CEO, 2K Biologics
11:30 Atherosclerosis Vaccination: From Immunological Concepts to Clinical Translation
Dr Jan Nilsson, Professor of Medicine, Lund University
11:50 Advax-CpG adjuvanted Alzheimer’s vaccines
Dr Nikolai Petrovsky, Founder & Research Director, Vaxine
12:10 3HOTP – A mimotope vaccine with anti-obesity and broader metabolic benefits
Dr Bert Binas, CSO, 3H Bio
12:30 Closing Panel Discussion – Common themes and challenges in unconventional vaccine development
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events